Diabetes Obes Metab 27(2):806815 Simms-Williams N, Treves N, Yin H, Lu S, Yu O, Pradhan R et al (2024) Effect of combination treatment with glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors on incidence of cardiovascular and serious renal events: population-based cohort study
Rather than focusing on one superfood, the strongest evidence supports an overall eating pattern that emphasizes minimally processed, fiber-rich foods
Prescribing these medications for brain protection alone would be off-label, and the human evidence is not strong enough to justify it outside of trial settings
Having a physician on board means someone can monitor this response and adjust dosages or strategies as needed
These can be signs of pancreatitis
As GLP-1 patches are not yet FDA-approved, they will not be covered by insurance